Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Inferring therapeutic targets from heterogeneous data: HKDC1 is a novel potential therapeutic target for cancer.

Li GH, Huang JF.

Bioinformatics. 2014 Mar 15;30(6):748-52. doi: 10.1093/bioinformatics/btt606. Epub 2013 Oct 24.

2.

Prioritizing therapeutics for lung cancer: an integrative meta-analysis of cancer gene signatures and chemogenomic data.

Fortney K, Griesman J, Kotlyar M, Pastrello C, Angeli M, Sound-Tsao M, Jurisica I.

PLoS Comput Biol. 2015 Mar 18;11(3):e1004068. doi: 10.1371/journal.pcbi.1004068. eCollection 2015 Mar.

3.

Candidate cancer-targeting agents identified by expression-profiling arrays.

Termglinchan V, Wanichnopparat W, Suwanwongse K, Teeyapant C, Chatpermporn K, Leerunyakul K, Chuadpia K, Sirimaneethum O, Wijitworawong P, Mutirangura W, Aporntewan C, Vinayanuwattikun C, Mutirangura A.

Onco Targets Ther. 2013 Apr 23;6:447-58. doi: 10.2147/OTT.S42858. Print 2013.

4.

From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma.

Daigo Y, Nakamura Y.

Gen Thorac Cardiovasc Surg. 2008 Feb;56(2):43-53. doi: 10.1007/s11748-007-0211-x. Epub 2008 Feb 24. Review.

PMID:
18297458
5.

Targeted therapies for lung cancer: clinical experience and novel agents.

Larsen JE, Cascone T, Gerber DE, Heymach JV, Minna JD.

Cancer J. 2011 Nov-Dec;17(6):512-27. doi: 10.1097/PPO.0b013e31823e701a. Review.

6.

MET as a possible target for non-small-cell lung cancer.

Sadiq AA, Salgia R.

J Clin Oncol. 2013 Mar 10;31(8):1089-96. doi: 10.1200/JCO.2012.43.9422. Epub 2013 Feb 11. Review.

7.

Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data.

Kim B, Lee HJ, Choi HY, Shin Y, Nam S, Seo G, Son DS, Jo J, Kim J, Lee J, Kim J, Kim K, Lee S.

Cancer Res. 2007 Aug 1;67(15):7431-8.

8.

Targeted therapies for non-small cell lung cancer.

Dempke WC, Suto T, Reck M.

Lung Cancer. 2010 Mar;67(3):257-74. doi: 10.1016/j.lungcan.2009.10.012. Epub 2009 Nov 14. Review.

PMID:
19914732
9.

MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene.

Fang R, Xiao T, Fang Z, Sun Y, Li F, Gao Y, Feng Y, Li L, Wang Y, Liu X, Chen H, Liu XY, Ji H.

J Biol Chem. 2012 Jun 29;287(27):23227-35. doi: 10.1074/jbc.M112.373084. Epub 2012 May 16.

10.

Advances in treatment of lung cancer with targeted therapy.

Cagle PT, Chirieac LR.

Arch Pathol Lab Med. 2012 May;136(5):504-9. doi: 10.5858/arpa.2011-0618-RA. Review.

PMID:
22540298
11.

Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets.

Motadi LR, Misso NL, Dlamini Z, Bhoola KD.

Int Immunopharmacol. 2007 Dec 20;7(14):1934-47. Epub 2007 Jul 31. Review.

PMID:
18039530
12.

Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.

Riess JW, Wakelee HA.

Clin Adv Hematol Oncol. 2012 Apr;10(4):226-34.

PMID:
22706483
13.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
14.

Integration of cancer gene co-expression network and metabolic network to uncover potential cancer drug targets.

Chen J, Ma M, Shen N, Xi JJ, Tian W.

J Proteome Res. 2013 Jun 7;12(6):2354-64. doi: 10.1021/pr400162t. Epub 2013 May 6.

PMID:
23590569
15.

CDA: combinatorial drug discovery using transcriptional response modules.

Lee JH, Kim DG, Bae TJ, Rho K, Kim JT, Lee JJ, Jang Y, Kim BC, Park KM, Kim S.

PLoS One. 2012;7(8):e42573. doi: 10.1371/journal.pone.0042573. Epub 2012 Aug 8.

16.

A robust tool for discriminative analysis and feature selection in paired samples impacts the identification of the genes essential for reprogramming lung tissue to adenocarcinoma.

Toh SH, Prathipati P, Motakis E, Kwoh CK, Yenamandra SP, Kuznetsov VA.

BMC Genomics. 2011 Nov 30;12 Suppl 3:S24. doi: 10.1186/1471-2164-12-S3-S24. Epub 2011 Nov 30.

17.

Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma.

Wang G, Ye Y, Yang X, Liao H, Zhao C, Liang S.

PLoS One. 2011 Jan 21;6(1):e14573. doi: 10.1371/journal.pone.0014573.

18.

Coordinated regulatory variation associated with gestational hyperglycaemia regulates expression of the novel hexokinase HKDC1.

Guo C, Ludvik AE, Arlotto ME, Hayes MG, Armstrong LL, Scholtens DM, Brown CD, Newgard CB, Becker TC, Layden BT, Lowe WL, Reddy TE.

Nat Commun. 2015 Feb 4;6:6069. doi: 10.1038/ncomms7069.

19.

Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.

Danesi R, de Braud F, Fogli S, de Pas TM, Di Paolo A, Curigliano G, Del Tacca M.

Pharmacol Rev. 2003 Mar;55(1):57-103. Review.

20.

Targeted therapies for advanced non-small-cell lung cancer: current status and future implications.

Custodio A, Méndez M, Provencio M.

Cancer Treat Rev. 2012 Feb;38(1):36-53. doi: 10.1016/j.ctrv.2011.04.001. Epub 2011 May 17. Review.

PMID:
21592673
Items per page

Supplemental Content

Write to the Help Desk